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Summary Seroepidemiology, the use of data on the prevalence of bio-markers of infection or vaccination, is a
potentially powerful tool to understand the epidemiology of infection before vaccination and to monitor
the effectiveness of vaccination programmes. Global and national burden of disease estimates for hepatitis
B and rubella are based almost exclusively on serological data. Seroepidemiology has helped in the design
of measles, poliomyelitis and rubella elimination programmes, by informing estimates of the required
population immunity thresholds for elimination. It contributes to monitoring of these programmes by
identifying population immunity gaps and evaluating the effectiveness of vaccination campaigns.
Seroepidemiological data have also helped to identify contributing factors to resurgences of diphtheria,
Haemophilus Influenzae type B and pertussis. When there is no confounding by antibodies induced by
natural infection (as is the case for tetanus and hepatitis B vaccines), seroprevalence data provide a
composite picture of vaccination coverage and effectiveness, although they cannot reliably indicate the
number of doses of vaccine received. Despite these potential uses, technological, time and cost constraints
have limited the widespread application of this tool in low-income countries. The use of venous blood
samples makes it difficult to obtain high participation rates in surveys, but the performance of assays based
on less invasive samples such as dried blood spots or oral fluid has varied greatly. Waning antibody levels
after vaccination may mean that seroprevalence underestimates immunity. This, together with variation in
assay sensitivity and specificity and the common need to take account of antibody induced by natural
infection, means that relatively sophisticated statistical analysis of data is required. Nonetheless, advances
in assays on minimally invasive samples may enhance the feasibility of including serology in large survey
programmes in low-income countries. In this paper, we review the potential uses of seroepidemiology to
improve vaccination policymaking and programme monitoring and discuss what is needed to broaden the
use of this tool in low- and middle-income countries.
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Introduction
Seroepidemiology, the collection and use of data on the
prevalence of antibodies (or less frequently, antigens) in
serum or related fluids to study the distribution and deter-
minants of infection, is a potentially powerful tool to help
design and monitor vaccination programmes [1, 2]. Its
application to individual vaccine-preventable diseases
(VPDs) depends on whether there is a serological marker
of past infection or vaccination, whether vaccine-induced
antibody can be distinguished from that following
infection, the extent and duration of protection conferred
by antibody, and whether the antibody level that corre-
lates with protection is known [3]. To date, seroepidemi-
ology has contributed most to the control and
elimination of poliomyelitis, measles and rubella – acute
viral VPDs where long-lasting immunity follows infection
or their respective replicating vaccines – but it has also
contributed to adapting vaccination strategies for non-
replicating vaccines, including diphtheria, Haemophilus
influenzae type B (Hib) and pertussis in high-income
countries.
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Challenges around specimen collection from represen-
tative populations, standardised high-quality conduct of
laboratory assays and appropriate statistical analysis have
limited the use of seroepidemiology in low- and middle-
income countries. The need for accurate data on popula-
tion immunity is increasing, however, as programmes
move towards eradication of poliomyelitis and elimina-
tion of measles and rubella, and also need to adapt to
maintain long-term control of other VPDs.
In this paper, we provide an overview of the use of
seroepidemiology to design, monitor and adapt strategies for
VPDs, briefly review the requirements to obtain high-quality
data and draw appropriate programmatic conclusions and
discuss how to increase its use in low- and middle-income
countries. The use of serological endpoints in clinical trials
of different vaccines, schedules or routes of administration,
another important application of serology to vaccine pro-
gramme design, is beyond the scope of this paper.
Uses of seroepidemiological data for vaccination
programme design and monitoring
Uses of seroepidemiology before vaccination is
introduced
For acute, antigenically stable infections, data on anti-
body prevalence by age are used in mathematical models
to estimate the age-specific force of infection, the burden
of disease (BOD) and theoretical immunity thresholds for
elimination of infection.
Seroprevalence data (Table 1) have been most impor-
tant for infections such as hepatitis B and rubella that are
frequently subclinical yet have a measurable serological
marker of infection. In the case of hepatitis B virus
(HBV), the viral surface antigen (HBsAg) is measured
whereas for other infections, specific antibody is used.
The outcomes of HBV infection are age-dependant and
include asymptomatic infection, acute hepatitis B illness
or chronic HBV infection, which predisposes to cirrhosis
and hepatocellular carcinoma [4]. Because data from
developing countries on chronic liver disease and cancer
are scarce, seroepidemiological data were critical to esti-
mate global disease burden and vaccination impact.
WHO classified countries into high (≥8%); medium (2–
7%) or low (<2%) levels of endemicity according to the
prevalence of HBsAg, an indicator of chronic HBV infec-
tion. In 1992, WHO recommended that HBV vaccine be
introduced in highly endemic countries by 1995 and in
all countries by 1997 [5]. Using data on the seropreva-
lence of hepatitis B in a large number of countries, math-
ematical modelling predicted that approximately
1.4 million HBV-related deaths would occur in the 2000
global birth cohort in the absence of vaccination, and
90% of these could be avoided through routine HBV vac-
cination starting at birth with 90% coverage [6].
Hepatitis A infection causes substantial morbidity in
high-income countries and is increasingly recognised as
important in middle and low-income countries. Infection
commonly manifests with acute hepatitis in adults but is
frequently subclinical in children under age 5 years.
Seroepidemiological studies of antibody prevalence have
been used to describe the epidemiology of hepatitis A
virus and identify countries (e.g. middle-income) or
groups (e.g. travellers) where vaccination may be most
relevant [7, 8].
Rubella infection in children and adults is frequently
subclinical or mild and until recently was not notified in
low-income countries. Estimates of the global burden of
congenital rubella syndrome and the potential impact of
vaccination strategies are therefore based on models of
the age-specific force of infection derived from studies of
the prevalence of rubella antibody, which persists lifelong
after infection. From seroepidemiological data reviewed
up to 1997, the global BOD was estimated at approxi-
mately 110 000 cases (plausible range 14 248–308 438
cases) of CRS per year [9], and little changed by 2010,
when 105 000 (95% CI: 54 000–158 000) CRS cases
were estimated globally [10].
Seroepidemiology also provides additional information
to complement clinical surveillance for VPDs for which the
sensitivity of reporting may be low and vary by age group,
geography or other factors affecting access to care. Thus,
serosurveys have helped describe the pre-vaccination epi-
demiology of varicella [11–15], yellow fever [16] and sea-
sonal [17, 18] or pandemic [19] influenza. Serological data
are less useful for VPDs that do not always generate robust
serum antibody responses (e.g. cholera, human papillo-
mavirus, rotavirus, typhoid) or for invasive bacterial infec-
tions [Haemophilus influenzae type b (Hib), meningococcal
and pneumococcal infection] where antibodies generated
by colonisation complicate the interpretation of seropreva-
lence data [3]. Nonetheless, serological studies have con-
tributed to elucidating the pre-vaccination epidemiology of
meningococcal A infection in Africa [20].
Uses of seroepidemiology after vaccination is introduced
Vaccination programme managers and their partners typ-
ically set targets for control or elimination of VPDs and
monitor progress via disease surveillance and vaccination
coverage measurement. These two sources of data are
combined to estimate the proportion of each birth cohort
that is protected, but the resulting estimates may be
biased by inaccurate coverage measurement [21], low
© 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1087
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Table 1 Uses of seroepidemiology to guide the control and elimination of vaccine-preventable diseases (VPDs)
Potential use of
seroepidemiological
data Requirements
Examples of vaccine-
preventable diseases
where used Comments
Pre-vaccination
Estimate burden
of disease
Either antigen or
antibody correlates
with infection.
Known natural history
of infection
Hepatitis B
Rubella
Contributed to hepatitis
A, measles, varicella,
yellow fever
Most useful for diseases
which are subclinical,
underrecognised or
undernotified, but also
contributes to better
analysis and
interpretation of clinical
surveillance data
Estimate
theoretical herd
immunity
thresholds
Age profiles of
seroprevalence
indicate age profile of
acquisition of
infection (i.e.
protective antibody
follows infection and
is stable over time)
Hepatitis B, measles,
rubella, poliomyelitis
Disease surveillance is an
alternative source of data
on age-specific infection
rates but seroprevalence
data are especially helpful
for infections that are
often subclinical
After vaccination
is introduced
Identify which
age groups to
include in
campaigns
Age profiles of
seroprevalence
indicate which age
groups lack immunity,
taking into account
waning antibody levels
after vaccination in
the absence of natural
boosting
Measles, rubella,
poliomyelitis
Seroprevalence data could
be used more often to
show which age groups
need campaigns to
eliminate infection
transmission
Determine the
duration of
immunity after the
primary series, the
need for and
timing of booster
doses
Antibody is main
correlate of protection
Diphtheria, Hib,
Meningococcus, Pertussis,
Tetanus
Long-term prospective
follow-up of vaccine trials
rarely feasible hence
seroprevalence studies
(often triggered by disease
resurgence) contribute to
decisions on including
booster doses to children
and/or adults in national
schedules
Monitor
progress towards elimination and
identify population
gaps in immunity
Targets have been set
for required
prevalence of antigen
or antibody
Antibody is main
correlate of protection
Hepatitis B, measles,
rubella, poliomyelitis,
tetanus
Clinical and
epidemiological relevance
of waning antibody levels
after vaccination need to
be understood, otherwise
population immunity may
be underestimated by
seroprevalence data
1088 © 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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vaccine effectiveness or duration of protection, or
changes in the sensitivity and specificity of surveillance
over time. Seroprevalence studies allow direct measure-
ment of the age-specific profile of susceptibility if the
assays are of known, and adequate, sensitivity and
specificity and representative population samples are
studied. Data on age-specific seroprevalence are impor-
tant to monitor overall programme progress, identify
population groups where immunity is low and inform
targeted vaccination strategies such as campaigns and/or
Table 1 (Continued)
Potential use of
seroepidemiological
data Requirements
Examples of vaccine-
preventable diseases
where used Comments
Investigate
causes of
resurgence of
disease
Antibody is main
correlate of protection
Diphtheria, Hib,
Meningococcus, Pertussis
Disease surveillance may
detect apparent increases
in incidence or outbreaks.
Serological data helpful to
investigate potential
causes, for example
changes in diagnostic or
reporting patterns,
waning immunity or
reduced vaccine
effectiveness following
changes in vaccine
formulations or schedules
Evaluate impact
of campaigns
Can account by study
design (e.g. pre- and
post-campaign
surveys) and/or
analysis for antibody
due to natural
infection or routine
immunisation
Measles, rubella,
poliomyelitis
Can be used for other
vaccines administered by
campaigns.
Without pre-campaign
serology, may be hard to
know the effect of the
campaign itself but can
determine whether target
immunity prevalence has
been reached
Estimate vaccine
coverage
There is an antibody
correlate of
vaccination
No natural infection
OR can distinguish
antibody induced by
vaccine from that by
infection or
colonisation
Predictable
immunogenicity under
wide range of
programme conditions
Antibody of known
duration (study
appropriate age
group)
Antibody levels
correlate with number
of doses received
Potential candidates are as
follows:
Tetanus toxoid
Hepatitis B vaccine
Measles, rubella,
poliomyelitis in settings
where infection has been
eliminated
Apart from hepatitis B and
tetanus, often difficult to
exclude natural infection.
The presence of antibody
does not tell you how
many doses have been
received even when
natural infection can be
excluded.
The absence of antibody
does not mean that the
child was not vaccinated
as no vaccine is 100%
effective even in ideal
conditions. Poor
vaccination practices can
reduce effectiveness, and
antibody levels wane over
time. Therefore difficult
to use seroprevalence data
to evaluate accuracy of
reported coverage data
© 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1089
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inclusion of booster doses in national schedules. They
can help to elucidate reasons for outbreaks and evaluate
the impact of vaccination campaigns on population
immunity. There is also great interest in using serological
data to infer routine vaccination coverage [22].
Hepatitis B control
WHO recommends that all regions and associated coun-
tries develop goals for hepatitis B control appropriate to
their epidemiological situation [23]. The Western Pacific
Region and Eastern Mediterranean Region have estab-
lished goals of reducing HBsAg prevalence to <1%. Sero-
surveys of HBsAg prevalence are the primary tool to
measure vaccination impact [23, 24]. Serosurveys have
also confirmed long-term protection against chronic infec-
tion (e.g. 94% vaccine effectiveness at approximately
20 years after vaccination in The Gambia [25]), despite
frequent occurrence of hepatitis infection among fully
vaccinated individuals. Such infection does not lead to
carriage or complications and the WHO therefore does
not recommend booster doses of HBV [23].
Measles and rubella elimination
The European region has established age-specific immu-
nity targets for measles taking account of different con-
tact patterns between different age groups [26]. Many
European countries collect serological data on multiple
infections periodically through the European Seroepi-
demiology Network (ESEN), as do Australia and the Uni-
ted States. Some countries collect sera via periodic
community-based surveys while others have systems to
store the residues remaining from microbiological or bio-
chemical investigations at participating laboratories and
sample these. Seroepidemiological data for 17 European
countries between 1996 and 2004 identified which were
on track to achieve measles elimination and which were
at risk of localised outbreaks or large epidemics [26].
Unfortunately, these data were not acted on in time to
avoid outbreaks in most of the countries identified at risk
[27, 28]. In Australia, data from three national serosur-
veys between 1996 and 2007 showed that measles popu-
lation immunity targets had been reached and sustained,
supporting evidence from coverage estimates, disease
notifications and genotyping showing that measles has
been eliminated [29]. In developing countries, seroepi-
demiological surveys in the 1990s identified age groups
and other risk groups with low prevalence of immunity
[30–32] and more recently have been used in Cambodia
to show that target levels of immunity for elimination
have been reached [33].
For rubella, ESEN data from 1994 to 1998 [34] and
from 1996 to 2004 [35] showed that despite the low
reported incidence in many countries, population immu-
nity was inadequate for elimination. Countries were
advised to conduct catch-up campaigns in older age
groups and selective targeting of older females to ensure
the necessary levels of protective immunity among
women of childbearing age. In Australia, national sero-
surveys provided estimates of the effective reproductive
rate for rubella of <0.5, well below the epidemic thresh-
old of 1, supporting the evidence from disease surveil-
lance of elimination [36]. In Singapore, selective
vaccination of schoolgirls began in 1976 and infant
measles–rubella vaccination in 1990, with additional
catch-up vaccination programmes [37]. Successful pro-
gramme implementation has been shown by consistently
high rubella vaccine coverage, a marked fall in reported
cases of acquired rubella to below the regional target of
<10 per million population, and the absence of indige-
nous CRS cases in 2012 and 2013 [37]. These data are
supported by regular seroepidemiological surveys that
confirm a fall in susceptibility among women of child-
bearing age, from 44% in 1975 to 28% in 1985 [38] to
11% in 2013 [37]. Rubella incidence and susceptibility of
adult women were, however, both higher in migrants
than in Singapore citizens, and further efforts to protect
adult women are urged.
Poliomyelitis eradication
As for measles and rubella, seroepidemiology is used to
determine if poliomyelitis immunity targets have been
reached, either at national-level or in high-risk areas of
endemic or recently endemic countries [39–41], allowing
better targeting of campaigns. Serosurveys have been used
to evaluate the use of bivalent oral polio vaccine (OPV)
in campaigns [42] and to predict the cost-effectiveness of
expanding the age range of campaigns [43].
In countries or regions that have eliminated wild polio-
virus transmission, seroepidemiology is useful to predict
the risk of transmission after importations [44–46]. Stud-
ies have helped to assess factors contributing to polio
outbreaks. In the Democratic Republic of Congo, residual
sera were available from HIV sentinel site surveillance of
pregnant women collected before an atypical outbreak of
wild poliovirus type 1 (WPV1) affected young adults in
2010–11. Sera were assayed for antibodies to polio-
viruses, and results showed that there had been immunity
gaps in women aged 15–29 years in the two provinces
with the highest numbers of cases in adults [47]. In Cam-
bodia, a large national population-based serosurvey iden-
tified immunity gaps in young women, highlighting the
1090 © 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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need for continued vigilance and surveillance [33]. In
Tajikistan, a large outbreak of WPV1 followed importa-
tion in 2010, leading to outbreak response vaccination
with monovalent OPV type 1 vaccine (mOPV1) followed
by trivalent OPV (tOPV) campaigns. A nationwide sero-
survey of 1–24-year-olds performed after the mOPV1
campaign but before the tOPV campaign showed high
prevalence of antibodies to type 1 poliovirus in all ages,
suggesting that the outbreak response had been effective,
but low prevalence of antibodies to type 3 poliovirus,
particularly in birth cohorts that had not been targeted in
previous campaigns and in certain regions. This suggested
that the outbreak resulted from suboptimal vaccine cov-
erage over a long time period, particularly in areas vacci-
nated only via routine services [48].
A major event in the polio eradication programme in
2016 is the global switch from trivalent to bivalent OPV
and at least one dose of inactivated polio vaccine (IPV).
Seroepidemiology is crucial to provide baseline data on
population immunity and to monitor any changes after
the switch [49–51].
Other vaccine-preventable diseases
Serosurveillance of meningococcal serogroup C antibodies
in the United Kingdom (UK) has shown that antibody
levels wane quickly after primary vaccination [52], high-
lighted the relationship between waning antibody titres
and declining vaccine efficacy [53] and shown the need
for a booster dose to be administered [54]. Seroepidemi-
ology is likewise being used to help monitor the impact
and duration of immunity after introduction of the new
conjugate meningococcal A vaccine in Africa [20, 55].
Diphtheria, once a major cause of childhood mortality in
Europe, became uncommon after mass vaccination began
and was targeted for elimination from the region by
2000, but a major resurgence occurred in all countries of
the former Soviet Union during the 1990s [56]. Sero-
surveillance for diphtheria coordinated through ESEN
from 1996 showed that many other European countries
had high proportions of adults with antibody levels
below the putative protection threshold; some childhood
vaccination schedules and vaccine formulations were less
immunogenic than others; booster doses of tetanus diph-
theria (Td) vaccine were important to maintain immu-
nity; and continued vigilance was indicated to ensure
high coverage and effectiveness of childhood vaccination
[57, 58]. Similar lessons have recently been reported from
serosurveys performed after outbreaks occurred in Thai-
land and Indonesia [59, 60]. In Tajikistan, where inci-
dence had been low since mass campaigns had controlled
the resurgence of the 1990s, a survey in 2010 showed
that only about one-third of 10–19-year-olds were
immune to diphtheria, leading to a national Td campaign
of 3–21-year-olds in 2012 [61].
Seroepidemiology has helped to identify contributing
factors to resurgences of Hib in the UK and pertussis in
several industrialised countries. In the UK, serological
data helped to demonstrate that protection after primary
Hib vaccination in infancy did not last as long as
expected, especially after use of a less immunogenic acel-
lular pertussis-containing combination Hib conjugate vac-
cine (DTaP-Hib) during 2000–2001. This led to catch-up
vaccination programs and a change in booster dose policy
[62]. In the case of pertussis, high antipertussis toxin
(PT) titres (>125 units/ml or >65.5 units/ml) are taken as
evidence of infection within the last year, because vacci-
nes rarely lead to such sustained high antibody levels
[63], although it may be difficult to use the data to esti-
mate disease incidence in young infants soon after vacci-
nation [64]. Diagnostic methods for pertussis vary within
and between countries and may vary by age group. Sero-
prevalence data are used to estimate true disease inci-
dence (often giving incidence rates several 100-fold
higher than those reported via clinical surveillance), to
conduct cross-country comparisons [64] and to identify
age groups contributing to disease transmission [65].
Serosurveillance of pertussis in seven European countries
showed that pertussis incidence was related to low vac-
cine coverage in some populations and to waning immu-
nity in high-coverage countries [66]. When combined
with either data from surveys on social mixing patterns
or with data from previous longitudinal studies on the
decay rate of antibody after infection, seroepidemiologi-
cal data have been a powerful tool to estimate the force
of infection and the basic reproductive number of pertus-
sis. Data on pertussis toxin titres from cross-sectional sur-
veys conducted before the introduction of adolescent
booster doses in five European countries led to estimated
infection incidence between 1% and 6% per year with
peaks in adolescents and to a lesser extent in young
adults. This suggested ongoing subclinical circulation of
pertussis due to waning of immunity after both vaccina-
tion and infection [67].
Evaluation of vaccination campaigns
Serosurveys conducted after campaigns are helpful to
show whether immunity targets have been reached and
assess whether the appropriate age groups were targeted
by the campaign by measuring susceptibility in other age
groups. For example, serosurveys in Niteroi, Brazil, in
1996 and in England and Wales in 1994 showed that
catch-up campaigns successfully reduced susceptibility to
© 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1091
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measles to very low levels in the target age groups
[68, 69]. In Australia, a campaign targeting school-age
children also achieved low susceptibility targets [70] but
a less-well funded or advertised programme targeting
adults aged 18–30 years failed to reduce susceptibility in
Victoria State and subsequent outbreaks continued to
affect young adults [71]. A serosurvey conducted 3 years
after a measles vaccine campaign in Lusaka, Zambia,
showed the rapid build-up of susceptible children after
the campaign and confirmed lower vaccine effectiveness
in HIV-infected than HIV-uninfected children (Moss
2009). Serosurveys have also been used to evaluate the
impact of campaigns on population rubella immunity
[72, 73].
To evaluate campaigns, pre- and post-campaign sur-
veys are ideal but to date have only been feasible on a
small scale. Studies using oral fluid assays in Ethiopia
[74] and Kenya [75] showed that measles campaigns
reduced susceptibility by 75% and 70%, respectively,
although target immunity levels were not reached in
Ethiopia, and older children who had not been included
in the campaign had high susceptibility.
Estimation of routine vaccination coverage
Vaccination coverage measurement is a critical part of
monitoring programme performance but both routine
reports and community-based surveys are subject to many
potential biases [21, 76, 77]. There is therefore interest in
using seroprevalence as an indicator of coverage of infant
or adult vaccination. To infer vaccination coverage from
seroprevalence data, either there must be no natural
infection occurring in the area or antibody induced by
vaccine should be distinguishable from that following
infection; there should be known vaccine immunogenicity
under a wide range of programme conditions, antibody
should have known duration after primary vaccination
and the appropriate age group should be studied, and
antibody levels should correlate with the number of doses
of vaccine received and be identified precisely and accu-
rately by a field-friendly assay [21, 22].
Vaccine-induced immunity can only be distinguished
from natural immunity for tetanus, hepatitis B and in cer-
tain settings for poliomyelitis, measles and rubella where
natural infection has been eliminated. Serosurveys have a
potentially important role in monitoring progress towards
elimination of neonatal tetanus, because it is especially
difficult to use vaccination coverage data to predict the
proportion of women of childbearing age or the propor-
tion of live births that are protected against tetanus.
Tetanus toxoid-containing vaccines are recommended
throughout life, the primary series being given in infancy
and booster doses thereafter, with a cumulative total of 5
or 6 doses (depending on the schedule) considered to
offer protection through at least the childbearing years.
Irrespective of childhood vaccinations, in developing
countries, pregnant women are usually offered two doses
of tetanus toxoid vaccine during each pregnancy but
cards are rarely kept, and information on doses received
prior to the current pregnancy derives from maternal
reports in community-based surveys. A serosurvey in the
Central African Republic showed that the proportion of
neonates protected at birth was substantially underesti-
mated using reported data on vaccinations received com-
pared to tetanus antibody prevalence in mothers [78].
Data on the prevalence of tetanus antibody are therefore
a better indicator of population immunity and the likeli-
hood that neonatal tetanus has been eliminated [79].
It is difficult, however, to use seroprevalence data in
any age group to estimate vaccine coverage because the
absence of detectable antibody may indicate not having
been vaccinated or alternatively an insensitive assay, low
vaccine effectiveness or waning antibody levels after vac-
cination. The presence of antibody does not indicate how
many doses of vaccine were received, or whether they
were received in routine services or campaigns. For exam-
ple, in a recent study in three districts of Ethiopia, postu-
lated protective levels of tetanus antibodies were found in
67–94% of infants who had two documented doses of
pentavalent vaccine and in 80–95% of infants with three
documented doses, and even in those with only one docu-
mented dose, 40–80% had ‘protective’ levels [80].
Attempts to correlate tetanus antibody prevalence with
coverage of different vaccines will be further complicated
in countries that have conducted campaigns using group
A conjugate meningococcal vaccine having a tetanus tox-
oid carrier because this vaccine also stimulates tetanus
immunity [81, 82].
Although of limited use to measure vaccine coverage,
measles serosurveys can highlight potential problems with
storing, administering or recording measles vaccination.
A recent study in poor areas of Mexico and Nicaragua
found that high proportions of children aged 12–
23 months with documented measles vaccination were
seronegative and that these children were clustered in cer-
tain municipalities, raising concerns about vaccination
practices in those areas [83].
Discussion
Seroepidemiology can be a powerful tool to guide deci-
sion-making on vaccine introduction and vaccine sched-
ules and to monitor programme impact, particularly
when combined with mathematical modelling. If assays
1092 © 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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are sufficiently sensitive and specific, then population
immunity is measured directly, rather than being inferred
from imperfect measures of vaccination coverage and
insensitive disease surveillance. Repeated serosurveys can
better assess geographical and temporal trends than dis-
ease notification, which is dependent on health worker
practices and diagnostic test performance [65, 84, 85]. In
settings where infections are eliminated or near elimina-
tion and there are very few disease notifications, sero-
surveillance can detect immunity gaps before outbreaks
occur. Causes of immunity gaps include failure to vacci-
nate certain population groups [33, 86–90], in-migration
of unvaccinated persons [90, 91], reduced vaccine effec-
tiveness [83, 92] or waning vaccine-induced immunity
[93, 94]. Ideally, immunity gaps are identified in time to
prevent outbreaks. Coordinated and standardised sero-
surveillance across Europe and in Australia has allowed
comparison of the effectiveness and impact of different
vaccine formulations and schedules for diphtheria, Hib
and pertussis, and guided supplementary immunisation
activities against measles, polio and rubella.
Seroepidemiology has much potential for low-income
countries, to estimate hepatitis B and rubella burden and
monitor vaccination impact, identify age groups for vac-
cination campaigns against measles, polio and rubella,
investigate the need for and timing of booster doses of
diphtheria, Hib, pertussis and meningococcal vaccines,
monitor protection against tetanus in adult women and
their babies and identify populations at risk of outbreaks
of VPDs. Serosurveys are of increasing importance in the
end game of polio eradication, to identify high-risk areas
within large countries, to monitor the effectiveness of tar-
geted campaigns and to monitor population immunity
after changes in vaccine formulations and schedules.
Although seroprevalence of a given antibody cannot cur-
rently, for reasons outlined earlier, validate other mea-
sures of vaccination coverage, it can give a direct
measure of programme effectiveness in reaching target
population immunity levels.
Despite these potential applications, the use of seroepi-
demiology in low-income countries is limited by access
to high-quality laboratories and appropriate assays, and
logistical, communication, time and resource challenges
in conducting surveys that are representative of the popu-
lations of interest and have adequate participation rates,
especially if venous blood samples are required [22, 95].
Experience with less invasive specimens such as dried
blood spots (DBS) or oral fluid has been mixed. Oral
fluid performed well in studies in Ethiopia [74, 96] and
Kenya [75] but poorly in Bangladesh [97]. A study using
DBS in poor areas of Mexico and Nicaragua found very
low measles antibody prevalence (68% and 50%,
respectively) despite high reported vaccination coverage
and successful measles elimination in both countries [83].
Although the study showed internal consistency in that
antibody prevalence was lowest in areas with known
cold chain or vaccination recording problems, it is hard
to reconcile this low prevalence with the absence of
measles outbreaks. Suboptimal assay sensitivity cannot
be ruled out under the field conditions of DBS collection,
which differed from those in the prior validation study
of DBS compared to serum. In the Democratic Republic
of Congo, the prevalence of both measles and tetanus
antibodies measured on DBS samples during the 2013–
2014 Demographic and Health Survey was also far
below that expected (http://dhsprogram.com/pubs/pdf/
FR300/FR300.vpd.pdf, 21 February 2016). National
measles seroprevalence in children aged 6–59 months
was 64.4%, and although seroprevalence did rise with
age as expected in this country with ongoing large
measles outbreaks [98], the finding of only 50% seropos-
itivity in some of the provinces worst affected by the out-
break raises questions about assay sensitivity. Similarly,
the prevalence of tetanus antibodies was very low and
did not increase according to numbers of doses of vac-
cine received, even among children whose vaccination
card was seen. Neither of these large surveys included a
subsample for assay by gold standard assays on serum
from venous blood samples, which would allow valida-
tion of the assay performance under the field conditions
of the survey.
The situation is evolving, however, as laboratory and
field epidemiology capacity has expanded through global
laboratory networks for polio, measles [99], rubella and
others and epidemiology training programs [100, 101].
Well-conducted population-based surveys can achieve
high participation rates and although costly, usually pro-
vide data on multiple infections. Large-scale community-
based surveys are performed regularly in most developing
countries [102] and have shown the feasibility of collect-
ing capillary blood samples [103]. Developments in mul-
tiplex assays [79] will allow simultaneous assessment of
immunity to several antigens of interest in surveys. It will
nonetheless be good practice to include collection of
venous blood samples on a subsample for gold standard
assays with appropriate use of international reference
standards.
Improvement of assays that use minimally invasive
specimens such as oral fluid or DBS could increase the
acceptability of repeat surveys, which are preferable for
assessing vaccine coverage [104], vaccine immunogenic-
ity and campaign impact. In countries with high
attendance at health services, sentinel site surveillance
may be adequate to monitor trends, for example, in
© 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1093
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rubella and tetanus susceptibility among adult women
[105], as is performed for monitoring trends in HIV
[106].
Estimates of the spatiotemporal dynamics of individual
and population immunity to a variety of pathogens
would be a powerful tool for public health programmes
and will be facilitated by further improvements in labora-
tory assays to make them more user-friendly in low-
income settings [79], standardising laboratory assays to
make it easier to compare studies in different locations
[107], continuing development of statistical approaches
to analysing serological data including accounting for
waning antibody levels over time [108, 109], and studies
to clarify the relationship between antibody levels, the
number of doses of multidose vaccines received and the
duration since the last dose.
When considering undertaking a seroepidemiological
study, it is important to choose the priority public
health questions to which serology can contribute most
and hence the antigens/antibodies to be studied, identify
the populations of interest and the sampling method
most likely to provide a representative sample of those
populations, select the most appropriate laboratory
assays to use – balancing field friendliness with perfor-
mance characteristics and planning to use gold standard
assays at least on a subsample – and determine how
data will be managed, analysed and used. Although
seroepidemiology is regarded as an essential part of
comprehensive immunisation programme monitoring in
many industrialised countries, they are experiencing
financial and technical challenges to sustaining high-
quality serosurveillance systems [2, 110]. Further experi-
ence is needed to determine the feasibility, acceptability,
cost and most useful applications of seroepidemiology in
low-income countries.
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